Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

出版年份 2021 全文链接

标题

作者

关键词

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 39, Issue 15_suppl, Pages 9014-9014

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2021-06-02

DOI

10.1200/jco.2021.39.15_suppl.9014

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

向作者/读者发起求助以获取更多资源

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.